Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jincaopian Tablets for Chronic Pelvic Pain After Pelvic Inflammatory Disease
NCT05970783Phase 3Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic pelvic pain (CPP) comparing Jincaopian Tablets with Placebo (2 arms). Primary endpoint: Pain disappearance rate at 12 weeks. Started Nov 2022; status: recruiting.
02
Drugs
jincaopian
03
Conditions
chronic pelvic pain (CPP)
Beyond the preview
Go deeper on NCT05970783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970783.